Australian biotech market watch 25/11/09
Wednesday, 25 November, 2009
Australian stocks have slipped back after a a spike yesterday morning. As of midday today, the All Ordinaries is at 4,716, level for the day.
Prima BioMed (ASX:PRR) has dropped back to 15c after a small rise to 16.5c last week following the announcement the company was working with Professor Ian Frazer's team on an oral cervical cancer vaccine.
QRxPHarma (ASX:QRX), which is developing dual-opid pain treatment, MoxDuo, has also taken a tumble over the past week after its announcement it had secured another $21.6 million in capital last Monday. It's now fetching 83.5c, down from $1.20 prior to the announcement.
Sirtex Medical (ASX:SRX) has jumped over 10% since Friday to $7.10 after it established a Centers of Excellence programme recognising hospitals that make significant contributions to interventional oncology, including the use of Sirtex's own SIR-Spheres.
Of the majors, ResMed (ASX:RMD) is up 1% to $5.55, while Cochlear (ASX:COH) has bounced back to its high of yesterday, reaching $62.39, up 2.45% today, and CSL (ASX:CSL) is level at $31.52.
Primary Health Care (ASX:PRY) has also gained 2% to $6.07, recovering from its dip in trading yesterday.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
